Experimental Alzheimer's drug reverses memory loss in mice by reprogramming gene activity

A team from the University of Barcelona has designed and validated in animal models an innovative compound with a pioneering mechanism of action for the treatment of Alzheimer's disease. Unlike current drugs, which mainly remove beta-amyloid plaques that accumulate in the brain, this new experimental drug reprograms the neuronal epigenome by correcting alterations in gene expression that contribute to the progression of the disease.